Scientific exchange · Dr. Noor Abbott

08 May 2026 · In person · Dr. Noor Abbott, Hospital Clínic Barcelona · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0039Safety

Safety flag

This record contains a potential adverse-event observation. It has been routed to Pharmacovigilance per SOP-PV-014 and is excluded from AI processing.

Location: Hospital Clínic Barcelona
Therapeutic area: Oncology
Country: Spain
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Infusion-reaction management

Scientific content used

VOYAGE-1 pivotal data summary
VTX core scientific deck v3.2

Questions raised

Is there subgroup data for patients with untreated brain metastases?

Notes

Scientific exchange with oncology pharmacist at Hospital Clínic Barcelona. Discussed infusion-reaction management.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 3
Depth of exchange: 2
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0039

Audit history (0)

All create, update and approval events for this record

No audit events in sample data